INDIANAPOLIS, IN — March 23, 2026 — Plug and Play, a global innovation platform, together with Indiana University Launch Accelerator for Biosciences (IU LAB), Indiana University Health, Indiana’s largest healthcare system, and the Central Indiana Corporate Partnership (CICP) through BioCrossroads, announced the 12 companies selected for the second cohort of the Lifetech Accelerator in Indianapolis.

As part of the IU Health Incubator at IU LAB, the program is designed to bridge the gap between breakthrough laboratory discovery and real-world clinical application.

“Following the success of our inaugural cohort, we are thrilled to scale our impact with Batch 2,” said Brandon Noll, Director of Plug and Play Indiana. “Our objective is to identify and support the most ambitious founders globally while anchoring them within Indiana’s world-class life sciences ecosystem. The IU LAB initiative is setting a new gold standard for university-led innovation.”

The second cohort is composed primarily of U.S.-based startups, with one company headquartered in Canada. Building on insights from the inaugural cohort launched in September 2025, the team has refined the program to better meet the needs of participating companies. This cohort focuses on precision medicine and advanced diagnostics, with targeted support to help startups navigate commercialization, regulatory pathways, and clinical adoption challenges. 

“The momentum behind precision medicine and advanced diagnostics is transforming the future of healthcare, and Batch 2 of IU LAB’s Lifetech Accelerator reflects that shift in a powerful way,” said David Rosenberg, President and CEO of IU LAB. “These companies are redefining how we detect, diagnose, and treat disease, moving toward more personalized, data-driven care that improves outcomes and reduces costs. At IU LAB, our focus is to help accelerate that translation from breakthrough science to real-world clinical impact, doing so in partnership with IU Health, Plug and Play and the Central Indiana Corporate Partnership.”

The selected startups represent the forefront of healthcare innovation, advancing cutting-edge solutions across oncology, neuroscience, regenerative medicine, and digital health.

 

The Batch 2 Lifetech Cohort Includes:

1. Adipo Therapeutics — Developing a first-in-class therapeutic for obesity that triggers “fat browning” to increase energy expenditure through mitochondrial biogenesis.
2. AnuBio — Leveraging AI-driven immunomodulation to develop potentially curative cancer therapies.
3. Cerevia Neuroscience — Building a closed-loop neuromodulation platform integrating deep TMS, functional MRI, and AI to treat dementia.
4. ENF Medical, LLC — Developing ENgraft, a scalable, bioresorbable bone graft platform designed to regenerate bone and reduce revision surgeries.
5. Motley Bio — Utilizing multiomics to unlock and target early-stage disease biology.
6. NextStepCare — A remote patient monitoring platform optimized for musculoskeletal health.
7. Oncodea – Creating non-invasive, affordable technology for ultra-early detection of multiple cancers.
8. Orbits Oncology — Scaling precision oncology solutions to expand patient access.
9. RNA Revive — A next-generation RNA platform enabling long-lasting, low-dose protein therapeutics for osteoporosis and liver disease.
10. Signaiture — Accelerating next-generation quality testing for life sciences manufacturing with improved speed and accuracy.
11. WearableDose — Enhancing radiotherapy safety and efficacy through an electronic polymer detector that precisely measures radiation delivery to tumors.
12. WittGen, Inc. — Utilizing GenAI-powered “virtual patients” to simulate clinical trials and strengthen regulatory success.

 

“It’s notable that such a strong cohort of startups were interested in participating in this batch, which reflects the increasing national visibility of IU LAB’s accelerator program,” said Mike Bolinder, Chief Innovation Officer of BioCrossroads. “BioCrossroads is poised to support these startups as they progress their assets and connect them with the spectrum of resources available within Indiana’s collaborative life sciences community.”

 

Launched in September 2025, the IU LAB Lifetech Accelerator was created by Plug and Play in collaboration with Indiana University, IU Health, and regional partners to strengthen Indiana’s position as a leader in life sciences innovation. The program supports startups developing breakthroughs in therapeutics, diagnostics, medical devices, and biotechnology through mentorship, investor access, and corporate collaboration.

 

To learn more about Plug and Play Lifetech, visit: https://www.plugandplaytechcenter.com/industries/lifetech.

 

About Plug and Play

Plug and Play is the leading innovation platform, connecting startups, corporations, venture capital firms, universities, and government agencies. Headquartered in Silicon Valley, we're present in 60+ locations across 5 continents. We offer corporate innovation programs and help our corporate partners in every stage of their innovation journey, from education to execution. We also organize startup acceleration programs and have built an in-house VC to drive innovation across multiple industries where we've invested in hundreds of successful companies, including Dropbox, Guardant Health, Honey, Lending Club, N26, PayPal, and Rappi. To get in contact with Plug and Play, visit www.plugandplaytechcenter.com/.    

 

About IU LAB
IU LAB is Indiana University’s signature life science innovation initiative. Located at 16 Tech Innovation District, IU LAB is charged with advancing life science innovation, commercializing research, and training the next generation of life science leaders. For more information, visit iulab.iu.edu. 

 

About IU Health
Indiana University Health is dedicated to offering highly-skilled, patient-centered care. Named among U.S. News & World Report’s 2025-2026 Best Hospitals as a High Performing hospital in four specialties, IU Health Medical Center is the only academic medical center in the state. The distinctive partnership with the Indiana University School of Medicine – one of the nation’s leading medical schools – equips our highly-skilled physicians with access to innovative treatments using the latest research and technology.

 

About BioCrossroads 
BioCrossroads (www.biocrossroads.com) is Indiana’s initiative to grow the life sciences, a public-private collaboration that supports the region’s research and corporate strengths while encouraging new business development. BioCrossroads provides money and support to life sciences businesses, launches new life sciences businesses (Indiana Health Information Exchange, Monarch LifeSciences, Fairbanks Institute for Healthy Communities, BioCrossroadsLINX, and Datalys Center) expands collaboration and partnerships among Indiana’s life science institutions, promotes science education and markets Indiana’s life sciences industry.
 

Media Relations Contact

Jacky Tsang

Senior Communications & PR Associate

press@pnptc.com